Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Novonesis

400.60 DKK

+3.06 %

Less than 1K followers

NSIS B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Compare
+3.06 %
+3.41 %
-1.28 %
-15.15 %
-1.74 %
-2.98 %
-6.38 %
+17.58 %
+982.70 %

Novonesis is a biochemistry company. The company develops enzymes and various microorganisms for industrial use. The enzymes are a protein used in a number of different industries, mainly in the agricultural and food industries. Novonesis products are used in various foods and clothing and the company holds sales on a global level. Novonesis was founded in 1921 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
187.6B DKK
Turnover
312.2M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.2.
2026

Annual report '25

23.3.
2026

General meeting '26

All
Press releases
ShowingAll content types
Regulatory press release11/21/2025, 9:47 AM

Trading by management and close relations of management

Novonesis
Regulatory press release11/7/2025, 3:39 PM

Trading by management and close relations of management

Novonesis
Regulatory press release11/7/2025, 9:34 AM

Major shareholder announcement

Novonesis

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release11/6/2025, 10:12 AM

Novonesis delivered 8% organic sales growth in the first nine months of 2025

Novonesis
Regulatory press release11/6/2025, 6:57 AM

8% organic sales growth after first nine months. Full-year organic sales growth narrowed upwards.

Novonesis
Regulatory press release11/4/2025, 2:11 PM

Trading by management and close relations of management

Novonesis
Regulatory press release9/10/2025, 12:09 PM

Major shareholder announcement

Novonesis
Regulatory press release9/2/2025, 10:57 AM

Trading by management and close relations of management

Novonesis
Regulatory press release8/28/2025, 10:19 AM

Amendment: Trading by management and close relations of management

Novonesis
Regulatory press release8/28/2025, 9:51 AM

Trading by management and close relations of management

Novonesis
Regulatory press release8/22/2025, 2:43 PM

Trading by management and close relations of management

Novonesis
Regulatory press release8/22/2025, 10:32 AM

Trading by management and close relations of management

Novonesis
Press release8/21/2025, 6:03 AM

Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%

Novonesis
Regulatory press release8/21/2025, 5:58 AM

Interim report H1 2025

Novonesis
Press release8/20/2025, 5:35 PM

2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement

Novonesis
Regulatory press release8/20/2025, 3:45 PM

2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement

Novonesis
Regulatory press release7/21/2025, 9:56 AM

Major shareholder announcement

Novonesis
Press release7/7/2025, 6:33 AM

Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe

Novonesis
Regulatory press release6/30/2025, 4:59 PM

Transactions under Novonesis’ share buyback program

Novonesis
Regulatory press release6/23/2025, 1:31 PM

Transactions under Novonesis’ share buyback program

Novonesis
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.